UAR Journal of Multidisciplinary Studies (UARJMS)
ISSN: XXXX-XXXX (Online)
Journal Home Page
Volume- I Issue- I (March) 2025
Frequency: Monthly

Review Article

Impact of HIV on Vaso-Occlusive Crisis Frequency in Sickle Cell Disease: A Review

*Emmanuel Ifeanyi Obeagu[1] and Francisca Ifeoma Osunwanne[2]

[1]Department of Biomedical and Laboratory Science, Africa University, Zimbabwe,
[2]Department of Nursing Science, Faculty of Health Sciences, Imo State University, Owerri, Imo State, Nigeria.

***Corresponding author:** Emmanuel Ifeanyi Obeagu

Abstract

Sickle cell disease (SCD) and HIV are chronic conditions with overlapping pathophysiological mechanisms that can significantly impact patient outcomes. Vaso-occlusive crises (VOCs), a hallmark of SCD, result from inflammation, endothelial dysfunction, and microvascular occlusion. HIV, through chronic immune activation, endothelial injury, and hematologic alterations, may influence the frequency and severity of VOCs. The interaction between these two diseases creates a complex clinical scenario that warrants further investigation. HIV-induced chronic inflammation and endothelial dysfunction may exacerbate VOCs by increasing oxidative stress, promoting coagulation abnormalities, and altering red blood cell adhesion properties. Additionally, hematologic complications such as anemia and bone marrow suppression due to HIV further complicate SCD progression. While antiretroviral therapy (ART) has improved HIV outcomes, its impact on VOCs remains unclear, with some regimens potentially exacerbating vascular complications while others may reduce systemic inflammation and endothelial damage.

Keywords: HIV, Sickle Cell Disease, Vaso-Occlusive Crisis, Endothelial Dysfunction, Inflammation

Introduction

Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by chronic hemolysis, recurrent vaso-occlusive crises (VOCs), and progressive organ damage. VOCs are the most common and debilitating complications of SCD, resulting from the occlusion of small blood vessels by sickled red blood cells (RBCs), leukocytes, and platelets. These episodes lead to ischemia, severe pain, and end-organ complications. The frequency and severity of VOCs vary among individuals, influenced by genetic, environmental, and comorbid conditions. One such comorbidity that may significantly affect VOC occurrence is HIV infection.[1-2] HIV remains a global health challenge, particularly in regions with high SCD prevalence, such as sub-Saharan Africa. HIV primarily targets the immune system, leading to progressive immunosuppression, chronic inflammation, and increased susceptibility to opportunistic infections. The virus also has profound effects on the hematologic system, causing anemia, thrombocytopenia, and neutropenia, which can complicate SCD progression. The overlapping pathophysiology of SCD and HIV suggests a potential bidirectional impact, where HIV may exacerbate SCD complications, including VOCs, and vice versa.[3-5] One of the key mechanisms by which HIV may influence VOC frequency is through chronic inflammation. In SCD, inflammation is driven by hemolysis-induced oxidative stress, endothelial activation, and increased expression of adhesion molecules. HIV infection further amplifies systemic inflammation through persistent immune activation and cytokine dysregulation. Elevated levels of inflammatory mediators such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β) contribute to endothelial dysfunction and vascular injury, which are critical in VOC pathogenesis.[6-7]

Endothelial dysfunction is another crucial factor linking HIV and VOC frequency. In SCD, repeated cycles of hypoxia and reperfusion injury damage the endothelium, promoting vaso-occlusion. HIV exacerbates this condition by impairing endothelial nitric oxide production, increasing endothelial permeability, and inducing a procoagulant state. The combined effects of SCD and HIV on the endothelium may enhance RBC adhesion, platelet aggregation, and leukocyte recruitment, leading to more frequent and severe VOC episodes.[8] HIV-related hematologic abnormalities also play a significant role in VOC modulation. Anemia, commonly observed in both SCD and HIV, reduces oxygen delivery and increases sickling, potentially triggering more frequent VOCs. Additionally, HIV-associated bone marrow suppression may alter erythropoiesis, further contributing to anemia and VOC risk. Neutropenia and thrombocytopenia, common in HIV-infected individuals, can also affect the inflammatory and coagulation pathways, influencing VOC outcomes.[9-10] Antiretroviral therapy (ART) has transformed HIV

management, improving survival and reducing opportunistic infections. However, the effects of ART on VOC frequency remain unclear. Some ART regimens, particularly protease inhibitors, have been associated with endothelial dysfunction and metabolic complications that could exacerbate VOC risk. Conversely, effective viral suppression through ART may reduce chronic inflammation, potentially leading to a decrease in VOC episodes. [11-12]

Pathophysiological Mechanisms Linking HIV and VOC Frequency

1. Chronic Inflammation and Immune Activation

Both HIV and SCD are characterized by persistent inflammation, which plays a central role in the pathogenesis of VOCs. In SCD, chronic hemolysis leads to the release of free hemoglobin and heme, triggering oxidative stress and endothelial activation. This process enhances the expression of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), promoting the adhesion of sickled red blood cells (RBCs), leukocytes, and platelets to the endothelium. HIV further exacerbates inflammation through immune activation, leading to elevated levels of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). These inflammatory mediators contribute to endothelial dysfunction, vascular injury, and increased VOC frequency in co-infected individuals.[13-15]

2. Endothelial Dysfunction and Vascular Injury

Endothelial dysfunction is a key driver of VOCs and is worsened by HIV infection. In SCD, endothelial cells are chronically activated due to hemolysis and ischemia-reperfusion injury, leading to reduced nitric oxide (NO) bioavailability and increased oxidative stress. HIV infection further impairs endothelial function by promoting vascular inflammation, increasing endothelial permeability, and disrupting normal coagulation pathways. The combined effects of SCD and HIV on the endothelium create a prothrombotic environment that enhances RBC adhesion and microvascular occlusion, increasing the likelihood of VOC episodes. Additionally, HIV proteins such as Tat and gp120 have been shown to directly damage endothelial cells, further contributing to vascular dysfunction.[16-18]

3. Hematologic Abnormalities and Altered Erythropoiesis

HIV infection induces a range of hematologic abnormalities, including anemia, thrombocytopenia, and neutropenia, which may impact VOC frequency. Anemia in HIV is often multifactorial, resulting from chronic inflammation, nutritional deficiencies, and bone marrow suppression due to viral infection or antiretroviral therapy (ART). In SCD, anemia is primarily caused by hemolysis, and the additional burden of HIV-related anemia may exacerbate hypoxia, increasing sickling and VOC risk. Moreover, HIV-associated bone marrow dysfunction can impair erythropoiesis, leading to inadequate RBC production and an increased tendency for sickled cells to persist in circulation.[19-20]

4. Hypercoagulability and Thrombosis

HIV and SCD are both prothrombotic conditions, increasing the risk of vascular occlusion and VOCs. In SCD, chronic hemolysis leads to the release of free hemoglobin, which scavenges NO and promotes platelet activation. Additionally, circulating microparticles from damaged RBCs contribute to coagulation abnormalities. HIV infection further enhances this hypercoagulable state by inducing endothelial activation, increasing tissue factor expression, and altering fibrinolysis. Studies have shown that HIV-infected individuals have elevated levels of procoagulant markers such as D-dimer, fibrinogen, and von Willebrand factor, all of which contribute to thrombotic events. The combination of these factors in HIV-SCD co-infected patients may lead to more frequent and severe VOCs.[21-23]

5. Oxidative Stress and Red Blood Cell Dysfunction

Oxidative stress plays a crucial role in both SCD and HIV pathogenesis. In SCD, recurrent ischemia-reperfusion injury generates reactive oxygen species (ROS), damaging RBC membranes and promoting hemolysis. HIV further exacerbates oxidative stress by increasing mitochondrial dysfunction, depleting antioxidant reserves, and inducing chronic inflammation. Increased oxidative damage to RBCs in co-infected individuals may enhance sickling and shorten RBC lifespan, further contributing to VOC frequency. Additionally, ART-related mitochondrial toxicity may worsen oxidative stress, leading to increased hemolysis and vaso-occlusion.[24-25]

6. Immune Dysregulation and Altered Leukocyte Function

Leukocytes play a significant role in VOC pathophysiology, with activated neutrophils contributing to endothelial adhesion and vascular occlusion. In HIV infection, immune dysregulation leads to abnormal neutrophil function, increased monocyte activation, and chronic immune activation, all of which may worsen VOC severity. Additionally, HIV-associated lymphopenia may impair immune surveillance, increasing susceptibility to infections that trigger VOCs. The interplay between immune dysfunction in HIV and inflammation in SCD creates a vicious cycle that promotes VOC recurrence and disease progression.[26-27]

7. Antiretroviral Therapy (ART) and Its Effects on VOCs

While ART has improved survival and quality of life for people living with HIV, its impact on VOC frequency in SCD remains unclear. Some ART regimens, particularly protease inhibitors, have been associated with metabolic complications, endothelial dysfunction, and cardiovascular disease, potentially increasing VOC risk. However, effective viral suppression through ART may reduce chronic inflammation and immune activation, potentially mitigating endothelial damage and VOC episodes. Understanding the specific effects of different ART regimens on SCD pathophysiology is essential for optimizing treatment strategies in co-infected individuals.[28-29]

Clinical Implications of HIV-SCD Co-Infection

1. Increased Frequency and Severity of Vaso-Occlusive Crises (VOCs)

HIV-SCD co-infected individuals may experience more frequent and severe VOCs due to the compounded effects of chronic inflammation, endothelial dysfunction, and hematologic abnormalities. Persistent immune activation in HIV promotes systemic inflammation, leading to increased adhesion of sickled red blood cells (RBCs) to the endothelium and higher risks of

microvascular occlusion. Additionally, HIV-induced endothelial injury and oxidative stress further exacerbate vascular dysfunction, contributing to prolonged and more painful VOC episodes. Clinically, this translates to higher hospitalization rates, increased need for opioid analgesia, and greater overall disease burden in co-infected patients.[30-31]

2. Higher Risk of Anemia and Blood Transfusion Requirements

Both HIV and SCD are associated with chronic anemia, but co-infection may worsen the condition due to multiple contributing factors, including hemolysis, bone marrow suppression, nutritional deficiencies, and ART-related myelosuppression. Severe anemia increases the risk of hypoxia-induced sickling and VOCs, leading to a higher dependency on blood transfusions. However, frequent transfusions raise concerns about iron overload, alloimmunization, and transfusion-transmitted infections, necessitating careful monitoring and iron chelation therapy in co-infected patients. Managing anemia effectively in HIV-SCD individuals is crucial for preventing VOCs and maintaining overall quality of life.[32-33]

3. Increased Susceptibility to Infections

HIV-SCD co-infected individuals have a compromised immune system due to both conditions, making them more vulnerable to bacterial, viral, and fungal infections. SCD patients are already at increased risk for infections due to functional asplenia and impaired immune responses, and HIV exacerbates this by depleting CD4+ T cells and impairing macrophage function. Common infections such as pneumonia, osteomyelitis, and sepsis may occur more frequently and with greater severity, leading to higher morbidity and mortality. Prophylactic antibiotics, routine vaccinations (including pneumococcal, meningococcal, and influenza vaccines), and strict infection control measures are essential for reducing infectious complications in this population.[34-35]

4. Complications Related to Antiretroviral Therapy (ART)

While ART has significantly improved HIV survival rates, its impact on SCD progression and VOC frequency is not fully understood. Some ART regimens, particularly protease inhibitors, have been linked to endothelial dysfunction, metabolic complications, and mitochondrial toxicity, all of which may contribute to increased VOC risk. Conversely, effective viral suppression through ART may reduce chronic inflammation and immune activation, potentially mitigating VOC frequency. Clinicians must carefully select ART regimens that minimize hematologic and vascular complications while ensuring optimal HIV control in SCD patients. Regular monitoring of hemoglobin levels, liver function, and metabolic parameters is crucial when managing ART in co-infected individuals.[36-37]

5. Increased Risk of End-Organ Damage

Both HIV and SCD contribute to progressive multi-organ damage, including renal dysfunction, pulmonary hypertension, and cardiovascular complications. In SCD, chronic hemolysis leads to kidney injury and endothelial dysfunction, while HIV-related nephropathy and hypertension further increase the risk of renal failure. Pulmonary hypertension, a common complication in SCD, may be worsened by HIV-induced vascular inflammation and immune dysregulation. Additionally, the combined cardiovascular risks associated with SCD-related endothelial dysfunction and HIV-related atherosclerosis increase the likelihood of stroke and other cardiovascular events. Regular screening for renal function, echocardiography for pulmonary hypertension, and aggressive management of cardiovascular risk factors are essential in co-infected patients.[38]

6. Challenges in Pain Management

Pain management in HIV-SCD co-infected individuals is particularly challenging due to overlapping neuropathic and inflammatory pain mechanisms. Chronic VOC-related pain may be exacerbated by HIV-associated neuropathy, which results from direct viral effects on the nervous system and ART-induced mitochondrial toxicity. Standard opioid-based pain management strategies must be balanced with concerns about opioid dependence, side effects, and potential drug interactions with ART. Integrative pain management approaches, including non-opioid analgesics, physical therapy, and psychological support, may help improve quality of life while minimizing opioid-related complications.[39]

7. Need for Multidisciplinary Care and Tailored Treatment Approaches

The complexity of HIV-SCD co-infection necessitates a multidisciplinary approach involving hematologists, infectious disease specialists, nephrologists, and pain management experts. Coordinated care is essential for optimizing treatment outcomes, managing complications, and improving overall survival. Tailored therapeutic strategies should focus on reducing inflammation, preventing VOCs, managing anemia, and selecting appropriate ART regimens that minimize hematologic and vascular complications. Regular follow-up, patient education, and adherence support are critical in ensuring successful long-term management of HIV-SCD co-infected individuals.[40]

Therapeutic Considerations

1. Optimizing Antiretroviral Therapy (ART) for SCD Patients

The selection of ART regimens in HIV-SCD co-infected patients requires careful consideration due to potential drug interactions, hematologic toxicity, and metabolic complications. Certain ART drugs, such as zidovudine (AZT) and some protease inhibitors, can exacerbate anemia, bone marrow suppression, or oxidative stress, potentially worsening vaso-occlusive crises (VOCs). Newer ART options, such as integrase inhibitors (e.g., dolutegravir), offer better tolerability with fewer hematologic side effects. Future research should focus on assessing the long-term effects of different ART regimens on SCD progression, VOC frequency, and overall disease outcomes.[41]

2. Anti-Inflammatory and Endothelial-Protective Strategies

Given the central role of inflammation and endothelial dysfunction in both HIV and SCD, anti-inflammatory therapies may help mitigate VOC frequency. Hydroxyurea, a standard treatment for SCD, reduces inflammation, increases fetal hemoglobin (HbF) levels, and improves RBC deformability. Its potential benefits in HIV-SCD co-infected individuals warrant further investigation. Additionally, novel anti-inflammatory agents, such as JAK inhibitors, statins, and endothelin receptor antagonists, may provide

endothelial protection and reduce VOC risk. Future clinical trials should explore these therapeutic strategies in co-infected patients to determine their efficacy and safety.[42]

3. Managing Anemia and Reducing Blood Transfusion Dependency

Anemia is a major challenge in HIV-SCD co-infected individuals, increasing the risk of VOCs and worsening overall health status. While blood transfusions are commonly used to manage severe anemia, repeated transfusions can lead to iron overload, alloimmunization, and other complications. Alternative strategies, such as erythropoiesis-stimulating agents (e.g., erythropoietin), iron chelation therapy, and novel RBC-modifying agents like voxelotor, may help reduce transfusion dependence. Further studies are needed to determine the safety and efficacy of these interventions in HIV-SCD patients.[43]

4. Addressing Hypercoagulability and Thrombotic Risk

Both SCD and HIV contribute to a hypercoagulable state, increasing the risk of thrombosis and VOCs. Antiplatelet agents (e.g., aspirin, P2Y12 inhibitors) and anticoagulants (e.g., low-molecular-weight heparin, direct oral anticoagulants) have been proposed as potential therapeutic options for reducing VOC-related complications. However, balancing the risk of bleeding with the benefits of anticoagulation remains a challenge. Ongoing research should focus on identifying optimal anticoagulation strategies tailored to HIV-SCD co-infected individuals.[44]

5. Integrative Pain Management Approaches

Pain management in HIV-SCD patients is complex due to the overlapping mechanisms of VOC-related pain and HIV-associated neuropathy. While opioids remain the mainstay for acute VOC pain, chronic opioid use raises concerns about dependence, tolerance, and drug interactions with ART. Non-opioid pain management strategies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), neuropathic pain agents (e.g., gabapentin, pregabalin), and behavioral therapies, should be incorporated into treatment plans. Future studies should explore personalized pain management protocols that consider both VOC-related and neuropathic pain components.[45]

6. Preventing and Managing Infections

HIV-SCD co-infected patients are highly susceptible to infections due to immune dysfunction and functional asplenia. Comprehensive infection prevention strategies should include routine vaccinations (e.g., pneumococcal, meningococcal, influenza), prophylactic antibiotics (e.g., penicillin for SCD, cotrimoxazole for HIV), and early infection screening. Future research should explore novel immunomodulatory approaches that enhance immune resilience in this population.[46-47]

7. Precision Medicine and Biomarker-Guided Therapies

Advancements in precision medicine offer new opportunities for tailoring treatments based on individual genetic and molecular profiles. Biomarker-based approaches may help predict VOC risk, ART-related complications, and response to anti-inflammatory or anticoagulant therapies. Emerging technologies, such as single-cell transcriptomics and proteomics, could provide deeper insights into the unique pathophysiological interactions between HIV and SCD, leading to more targeted therapeutic interventions.[48]

Conclusion

HIV-SCD co-infection presents a complex clinical challenge due to the overlapping pathophysiological mechanisms of both diseases. The chronic inflammation, endothelial dysfunction, and immune dysregulation associated with HIV exacerbate the frequency and severity of vaso-occlusive crises (VOCs) in sickle cell disease (SCD) patients. Additionally, co-infection increases the risk of severe anemia, infections, thrombotic complications, and end-organ damage, requiring a multifaceted approach to management. While antiretroviral therapy (ART) has significantly improved HIV outcomes, its potential hematologic and vascular effects in SCD patients necessitate careful regimen selection and ongoing research.

A comprehensive treatment strategy for HIV-SCD co-infected individuals should include optimized ART regimens, anti-inflammatory therapies, endothelial-protective agents, and personalized pain management approaches. Preventive measures such as routine vaccinations, infection prophylaxis, and regular screenings for organ dysfunction are essential to improving patient outcomes. Future research should focus on precision medicine, biomarker-guided therapies, and novel pharmacologic interventions that target the unique pathophysiological interactions between HIV and SCD. Large-scale clinical trials are needed to establish evidence-based guidelines for managing this high-risk population effectively.

References

1. Owusu ED, Visser BJ, Nagel IM, Mens PF, Grobusch MP. The interaction between sickle cell disease and HIV infection: a systematic review. Clinical Infectious Diseases. 2015; 60(4):612-626.
2. Boateng LA, Ngoma AM, Bates I, Schonewille H. Red blood cell alloimmunization in transfused patients with sickle cell disease in sub-Saharan Africa; a systematic review and meta-analysis. Transfusion Medicine Reviews. 2019; 33(3):162-169.
3. Ola B, Olushola O, Ebenso B, Berghs M. Sickle Cell Disease and Its Psychosocial Burdens in Africa. InSickle Cell Disease in Sub-Saharan Africa 2024: 67-80. Routledge.
4. Makani J, Ofori-Acquah SF, Nnodu O, Wonkam A, Ohene-Frempong K. Sickle cell disease: new opportunities and challenges in Africa. The scientific world journals. 2013; 2013(1):193252.
5. Ochocinski D, Dalal M, Black LV, Carr S, Lew J, Sullivan K, Kissoon N. Life-threatening infectious complications in sickle cell disease: a concise narrative review. Frontiers in Pediatrics. 2020; 8:38.
6. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology, 2024; 2(1): 14-33
7. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
8. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health, 2024; 2 (1): 52-61
9. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A

Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024; 10(1):25-36.
10. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Asian J Dental Health Sci, 2024; 4(1):32-7. Available from: http://ajdhs.com/index.php/journal/article/view/62
11. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
12. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
13. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73 1
14. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20- 35
15. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIVExposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
16. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Newport International Journal of Biological and Applied Sciences (NIJBAS) 2023. http://hdl.handle.net/20.500.12493/14626
17. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. Circulation. 2023; 147(1):83-100.
18. Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV and its impact on atherosclerotic cardiovascular disease. Circulation research. 2024; 134(11):1515-1545
19. Hmiel L, Zhang S, Obare LM, Santana MA, Wanjalla CN, Titanji BK, Hileman CO, Bagchi S. Inflammatory and immune mechanisms for atherosclerotic cardiovascular disease in HIV. International journal of molecular sciences. 2024; 25(13): 7266.
20. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
21. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
22. Belisário AR, Blatyta PF, Vivanco D, Oliveira CD, Carneiro-Proietti AB, Sabino EC, de Almeida-Neto C, Loureiro P, Máximo C, de Oliveira Garcia Mateos S, Flor-Park MV. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. BMC Infectious Diseases. 2020; 20(1):638.
23. Bhowmik A, Banerjee P. Hematological manifestation in HIV infected children. J Coll Physicians Surg Pak. 2015; 25(2):119-123.
24. Gill AF, Ahsan MH, Lackner AA, Veazey RS. Hematologic abnormalities associated with simian immunodeficieny virus (SIV) infection mimic those in HIV infection. Journal of Medical Primatology. 2012; 41(3):214-224.
25. Nouraie M, Nekhai S, Gordeuk VR. Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study. Sexually transmitted infections. 2012; 88(7):528-533.
26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024; 2(1):33-45.
27. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
28. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
29. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
30. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIVPositive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
31. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
32. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
33. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
34. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
35. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
36. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
37. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. AIDS research and therapy. 2015; 12:1-8.
38. Enawgaw B, Alem M, Addis Z, Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar,

Northwest Ethiopia: a comparative cross-sectional study. BMC hematology. 2014; 14:1-7.

39. Gudina A, Wordofa M, Urgessa F. Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia. Plos one. 2024; 19(10): e0310239.
40. Geletaw T, Tadesse MZ, Demisse AG. Hematologic abnormalities and associated factors among HIV infected children pre-and post-antiretroviral treatment, North West Ethiopia. Journal of blood medicine. 2017:99-105.
41. Jegede FE, Oyeyi TI, Abdulrahman SA, Mbah HA, Badru T, Agbakwuru C, Adedokun O. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria. PLoS One. 2017; 12(3):e0174233.
42. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. Elite Journal of Haematology. 2024; 2(4):68-85.
43. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
44. Ciccacci F, Lucaroni F, Latagliata R, Morciano L, Mondlane E, Balama M, Tembo D, Gondwe J, Orlando S, Palombi L, Marazzi MC. Hematologic alterations and early mortality in a cohort of HIV positive African patients. PLoS One. 2020; 15(11):e0242068.
45. Ashenafi G, Tibebu M, Tilahun D, Tsegaye A. Immunohematological Outcome Among Adult HIV Patients Taking Highly Active Antiretroviral Therapy for at Least Six Months in Yabelo Hospital, Borana, Ethiopia. Journal of Blood Medicine. 2023:543-554.
46. Obeagu EI, Goryacheva OG. The Role of Inflammation in HIV and Sickle Cell Disease Co-Morbidity. Lifeline HIV, 2025; 3(1): 1-12
47. Obeagu EI, Goryacheva OG. Oxidative Stress in HIV and Sickle Cell Disease: A Double Burden. Lifeline HIV, 2025; 3(1): 13-24
48. Obeagu EI, Goryacheva OG. HIV and Sickle Cell Disease: A Focus on Liver Dysfunction. Lifeline HIV, 2025; 3(1): 25-40